Document Type : Research Article
Background:Atypical pneumonia is caused by the SARS CoV-2 virus in persons who
have it. Inflammation is induced by the virus, which aids viral reproduction,
dissemination, tissue injury, and hypoxia. Bevacizumab is a prominent anti-VEGF
monoclonal antibody that has been approved by the USFDA for colorectal carcinoma,
non-small cell lung carcinoma, renal carcinoma, recurrent glioblastoma, cervical
carcinoma, and ovarian carcinoma. We conducted this study to look into the clinical
benefits of bevacizumab in combination with standard care for patients with moderate
to severe COVID-19 disease.
Materials and Methods: The present prospective study was conducted among patients
with moderate to severe COVID-19 pneumonia, admitted at CMC
MULTISPECIALITY HOSPITAL Hospital during SEP 2020 to june 2021. After taking
informed consent from relatives a pretested proforma was used to record the
demographic data, presenting symptoms, the changes of status of oxygen-support as
well as the symptom. Each eligible patient received two doses (400 mg) of bevacizumab
and arterial blood gas analysis, chest computed tomography (CT) scanning, chest Xray,
and laboratory tests were performed at baseline, Day 1 and Day 7 after start of
bevacizumab. To compare differences between different time points after intervention
and baseline point, a paired t-test or Wilcoxon matched-pairs signed-rank test was used
for quantitative data.
Results: In present study, the mean age of patients was 50.2±14.1 years. Majority of
enrolled patients were males (80.0%). The fever (85.0%) followed by cough (76.7%) and
dyspnoea (70.0%) were the common symptoms among enrolled patients. The mean
temperature of the enrolled patients was 99.3±1.4 F. CT chest showed that left lung
lesion ratio was 19.7±15.4% at baseline and it showed improvement and reduced to
12.1±4.3% and similar significant improvement was observed for right lung lesion ratio
(baseline: 35.2±14.9% vs Day 7: 17.2±13.9%). The discharge rate in our study was
65.0%. Due deteriorating of condition or addition of new complications, 18.3% of
patients were referred to higher centres for further management. The death rate was
16.7% in our study.
Conclusion: To reduce mortality in the global COVID-19 pandemic, the necessity for
efficient treatment with few complications should be prioritised. These 60 patients also
demonstrate bevacizumab's high efficacy in SARS CoV-2 patients.